



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/613,767	07/03/2003	Fu-Sheng Wang	11333/20	4833

757 7590 04/30/2010
BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, IL 60610

EXAMINER

SCHUBERG, LAURA J

ART UNIT

PAPER NUMBER

1657

MAIL DATE

DELIVERY MODE

04/30/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/613,767

Applicant(s)

WANG ET AL.

Examiner

LAURA SCHUBERG

Art Unit

1657

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 12 March 2010.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1, 3, 6, 8, 10-14 and 20-25 is/are pending in the application.
- 4a) Of the above claim(s) 8, 12 and 20-22 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 3, 6, 10, 11, 13, 14, 23-25 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
- Paper No(s)/Mail Date 3/12/2010
- 4) ☐ Interview Summary (PTO-413)
- Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 3/12/2010 has been entered.

Currently, claims 1, 3, 6, 8, 10-14, 20-25 are pending in the application.

Claims 1 and 23 have been amended. No claims have been newly canceled or newly added.

Claims 8, 12, 20-22 were withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected specie, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 05/18/2006.

Claims 1, 3, 6, 10, 11, 13, 14, 23-25 have been examined on the merits.

Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1, 3, 6, 10, 11, 13-14, 23-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sakata (Sysmex Journal International 2000) in view of Houwen (US 5,830,701), Walters et al (Laboratory Hematology 2000), Ota et al (Haematologia 2000) and Sysmex Europe 2003 (Feb 2003).

Amended claim 1 is drawn to a method of detecting a megakaryocyte comprising: preparing an assay sample by combining a sample comprising a cell with a reagent comprising a polymethine dye, wherein the preparing does not involve an immunological method; detecting fluorescent light and scattered light emitted by the cell; generating a scattergram from the detected light, wherein the scattergram comprises a predetermined megakaryocyte region; and detecting the megakaryocyte if a population exists in the predetermined megakaryocyte region of the scattergram generated from the detected fluorescent light and the detected scattered light, wherein the method executed by an automated hematology analyzer having the flow cytometer.

Claim 3 is drawn to wherein the detecting involves an automated hematology analyzer.

Claim 6 is drawn to wherein scattered light comprises side scattered light emitted by the cell.

Claim 10 is drawn to identifying the megakaryocyte region of the scattergram.

Amended claim 23 is drawn to a method of detecting a megakaryocyte comprising preparing an assay sample by combining a sample comprising a cell with a reagent comprising a polymethine dye and a hemolytic agent, wherein the preparing does not involve an immunological method; detecting scattered light and fluorescent

Art Unit: 1657

light emitted by the cell; generating a scattergram from the detected light wherein the scattergram comprises a predetermined megakaryocyte region; and detecting the megakaryocyte if a population exists in the predetermined megakaryocyte region of the scattergram generated from the detected fluorescent light and the detected scattered light, wherein the method executed by an automated hematology analyzer having the flow cytometer.

Claim 24 is drawn to wherein the scattered light comprises side scattered light.

Claim 25 is drawn to wherein the detecting involves an automated hematology analyzer.

Sakata teaches a method of detecting nucleated red blood cells (NRBC) with a reagent that comprises a fluorescent dye (polymethine) and a hemolytic agent and provides degree of cell staining information (p.41). Scattered light and fluorescent light are detected and a scattergram is generated (p.44). The detecting involves an automated hematology analyzer having a flow cytometer (XE-2100) (p.41). The preparing of the sample does not involve an immunological method. In addition, Sakata teaches that in the XE-2100, by developing and using optimum polymethine dyes not only for the NRBC channel, but also the 4 DIFF and RET channels, a wide variety of normal and abnormal cells can be classified and counted (p.42 column 2). Sakata also teaches that the automated hematology counter will be able to count all types of cells- including, in the future, cells presently considered to be "impossible" to count (p.45).

Sakata does not teach the use of the method to detect megakaryocytes or to determine if a population exists in a megakaryocyte region of a scattergram.

Houwen teaches the use of the automated hematology analyzer, SE-9000 (column 7 line 51), for the detection of megakaryocytes (column 4 line 35) and for the determining of the region of the scattergram where the megakaryocyte population exists (column 7 lines 53-55). The use of a flow cytometer operating on an optical principle is taught as an alternative particle analyzer (column 7 line 17). Houwen also teaches that there is a great benefit to the medical field in monitoring of hematopoietic progenitor cells (which includes megakaryocytes) in peripheral blood stem cell transplantation (column 11 lines 1-4). Where the detecting comprises passing the assay through an electrically charged aperture and identifying a change in direct current (DC) resistance and radio frequency (RF) resistance is taught as well as cell size information based on a change in DC and cell interior information based on a change in RF (column 7 lines 2-23). Houwen teaches obtaining cell information about the treated blood sample using a particle analyzer and constructing a cell distribution profile (scattergram); delineating a portion of the profile as a zone in which at least one subclass of hematopoietic progenitor cells appear; wherein the profile zone is delineated through the use of a control sample comprising hematopoietic progenitor cells and counting the cells in the zone (column 11). Examples of the cell interior information include lateral (side) scattered light (column 7 lines 7-10).

Walters teaches that a comparison between hematology analyzers Sysmex XE-2100 and Sysmex SE-9000 showed excellent correlation for all parameters except number of basophils (p.89). Walters also teaches that the Sysmex XE-2100 has proven

to be an accurate and precise high-speed analyzer and is suitable for both high volume laboratories and laboratories that test many abnormal samples (p.92).

Ota teaches that violet polymethine dye (VPM) is a megakaryocyte-specific stain that is clinically useful for estimating of megakaryocyte count, classification of megakaryocytes and identification of immature megakaryocytic cells (p.21).

Sysmex 2003 teaches the use of the Sysmex XE-2100 and the need for the recognition of platelets, giant platelets, megakaryocyte fragments and megakaryocyte nucleus (page 1).

One of ordinary skill in the art would have been motivated to use the method of Sakata for the detection of megakaryocytes because Sakata suggests that the method could be used for other cell types than NRBs (p.42 column 2 and p.45 column 1) and Houwen teaches that there is a great benefit to the medical field in monitoring of megakaryocytes (column 11 lines 1-4). The fact that Sysmex 2003 also teaches the need to observe and calculate megakaryocyte numbers along with the use of the XE-2100 would also motivate one of ordinary skill in the art to extend the use of this analyzer to include the monitoring of megakaryocytes as well. One of ordinary skill in the art would have been motivated to identify a megakaryocytic region in the scattergram generated by the method of Sakata because regions for other cell types are also generated upon detection. One of ordinary skill in the art would have been motivated to use side-scattered light when detecting megakaryocytes because Houwen teaches that this type of cell interior information is useful for detecting megakaryocytes. Using settings adjusted to display a megakaryocyte population would have been a

matter of routine optimization since the artisan of ordinary skill would recognize that the results would depend upon optimal settings of the hematology analyzer and comparison with manual and flow cytometry results would have allowed reference controls to ensure accuracy. One of ordinary skill in the art would have had a reasonable expectation of success because Walters teaches that the Sysmex XE-2100 (used by Sakata) showed excellent correlation with the Sysmex SE-9000 (used by Houwen to detect megakaryocytes) and Ota teaches that a polymethine dye (also used by Sakata with the Sysmex XE-2100) is specific for megakaryocytes allowing detection of megakaryocytes as well.

Therefore, the combined teachings of Sakata, Houwen, Walters, Ota and Sysmex Europe 2003 render obvious Applicant's invention as claimed.

Claims 11, 13, 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sakata (Sysmex Journal International 2000) in view of Houwen (US 5,830,701), Walters et al (Laboratory Hematology 2000), Ota et al (Haematologia 2000) and Sysmex Europe 2003 (Feb 2003) as applied to claims 1, 3, 6, 10, 23-25 above, and further in view of Tomer et al (Blood 1988).

Claim 11 is drawn to claim 10 wherein the identifying comprises 2 reference scattergrams, one with purified megakaryocytes and one substantially free of megakaryocytes and comparing them.

Claims 13 and 14 are drawn to claim 11 wherein the purified megakaryocyte comprises a cell induced from a CD34 positive hematopoietic cell by thrombopoietin.

Tomer teaches a method of detecting megakaryocytes that includes preparing an assay sample by combining bone marrow from normal human donors (p.1244 column 2) with fluorescent antibodies (dye) and a hemolytic agent (0.1% sodium citrate) (p.1245 column 1). Data collection of the fluorescence intensities and scattered light of each cell are carried out (p.1245 column). Scattergrams are generated by plotting scattered light and fluorescent light (p.1246 column 1). A megakaryocytic region is identified in the scattergrams by generating 2 reference scattergrams, one with purified megakaryocytes and the other without (p.1246 column 1). A population is determined to exist in a megakaryocytic region of the scattergram. The cell interior information is detected based on side-scattered light and the degree of cell staining information is detected based on fluorescent light emitted by the cell (p.1244 column 2). An automated hematology analyzer is also taught (p.1244 column 2).

Since Houwen teaches that the appearance zone of megakaryocytes is delineated based on the scattergram pattern for the appearance of megakaryocytes, one of ordinary skill in the art would have been motivated to include a reference scattergram without megakaryocytes as a negative control to improve the accuracy of the final result. One of ordinary skill in the art would have been motivated and had a reasonable expectation of success because Tomer was using such a negative control to identify a megakaryocyte region on a scattergram as well.

The purified megakaryocytes are inherently induced from CD34 positive hematopoietic cells by thrombopoietin (TPO) and this induction occurs *in vivo*. Since the claim language does not require the induction to be *in vitro*, this meets the limitations of claims 13 and 14 as claimed.

Therefore, the combined teachings of Sakata, Houwen, Walters, Ota, Sysmex Europe 2003 and Tomer render obvious Applicant's invention as claimed.

Response to Arguments

Applicant's arguments filed 3/12/2010 have been fully considered but they are not persuasive.

Applicant argues that the Sakata reference in view of Houwen, Walters and Ota relate to nucleated red blood cell measurement and do not disclose Applicant's claimed invention.

This is not found persuasive because one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

The primary reference, Sakata, teaches the same method of detecting as Applicant and includes the use of the same apparatus (XE-2100) except for the type of cell to be detected. The secondary references, combined with the teaching of Sakata

that the method could be applied to other cell types, provide motivation and reasonable expectation of success to apply the method of Sakata to the detecting of megakaryocytes as well. The method of Sakata uses the combination of fluorescent light and scattered light to detect nucleated red blood cells and suggests that this method be used to detect other cell types as well.

Applicant argues that the scattergram generated by the Sakata reference is not disclosed as being capable of detecting megakaryocytes. Applicant argues that the size of the megakaryocyte is so much larger than the size of the WBC that the scattergram of figure 4 in the Sakata reference is not able to set the megakaryocyte region because this region exists out of the range of the scattergram of figure 4.

This is not found persuasive because the ability to generate a scattergram for megakaryocytes is known in the art as described by Houwen and one of ordinary skill in the art would be able to modify the settings of the XE-2100 to achieve scattergrams of different cell types and sizes as suggested by Sakata and Sysmex Europe 2003 cited above.

Applicant argues that Sakata is silent to the detection of a megakaryocyte executed by an automated hematology analyzer having a flow cytometer.

This is not found persuasive because the analyzer used by Sakata is the XE-2100 which is the same analyzer used by Applicant (Applicant's Spec pages 9-10) and which inherently possesses the characteristics of an automated hematology analyzer having a flow cytometer.

Applicant argues that the Examiner's reasoning is inconsistent with the teachings of each of the cited references relied on to reject the claims. Applicant requests documentary evidence to support these conclusions be requesting an affidavit from the Examiner as the Applicant deems the conclusions must be from the Examiner's personal knowledge.

This is not found persuasive as all the statements and conclusions made by the Examiner are based on the disclosures of the above cited documents in the obviousness rejections as well as Applicant's own disclosure.

The Supreme Court recently states in *KSR v. Teleflex* (550 US82 USPQ2d 1385, 2007) "The same constricted analysis led the Court of Appeals to conclude, in error, that a patent claim cannot be proved obvious merely by showing that the combination of elements was "obvious to try." *Id.*, at 289 (internal quotation marks omitted). When there is a design need or market pressure to solve a problem and there are a finite number of identified, predictable solutions, a person of ordinary skill has good reason to pursue the known options within his or her technical grasp. If this leads to the anticipated success, it is likely the product not of innovation but of ordinary skill and common sense. In that instance the fact that a combination was obvious to try might show that it was obvious under §103." See also *M.P.E.P.* §2141.

Clearly there was an identified need for the analysis of a megakaryocyte population in the art based on the art cited above and the knowledge available to carry out that analysis as well as the suggestion that the Sakata method could be modified to analyze other needed cell types as well.

In view of the foregoing, when all of the evidence is considered, the totality of the rebuttal evidence of nonobviousness fails to outweigh the evidence of obviousness.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAURA SCHUBERG whose telephone number is (571)272-3347. The examiner can normally be reached on Mon-Fri 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on (571) 272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Art Unit: 1657

Laura Schuberg
Examiner
Art Unit 1657

/Laura Schuberg/